10/583979 APS Rec'd PCT/PTO 18 110151

> Express Mail No. EV668295287US Date of Deposit: June 22, 2006

> > **PATENT**

SLR:dm 06/22/06 5585-75922-01 545716 P104573US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Richard Ross Application No. Currently unknown

Filed: June 22, 2006

Confirmation No. Currently unknown

For: SUSTAINED RELEASE HYDROCORTISONE

TREATMENT

Examiner: Not yet assigned Art Unit: Not yet assigned

Attorney Reference No. 5585-75922-01

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Sheree Lynn Rybak, Ph.D. Registration No. 47,913

cc: Docketing

SLR:dm 06/22/06 5585-75922-01 536466.doc P104573US

10/583979. AP3 Rec'd PCIPTO 32 JUN 2000 No. EV668295287US

Attorney Docket Number	5585-75922-01
Application Number	Currently unknown
Filing Date	June 22, 2006
First Named Inventor	Ross
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number		Publication Date		Name of Applicant or Patentee		
					_			
	<u> </u>	I	FOREIG	N PATENT	DOCUM	ENTS		
Examiner's Initials*	Cite No. (optional)	Country	N	Number Publication		ion Date	Name of Applicant or Patentee	
		WIPO	WO 03	/015793 A1	02/27/2003		University of Sheffield	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS						
		Debattista et al., "Acute Antidepressant Effects of Intravenous Hydrocortisone and CRH						
		in Depressed Patients," Am. J. Psychiatry 157:1334-1337 (2000). Souêtre et al., "Circadian Rhythms in Depression and Recovery: Evidence for Blunted						
		Amplitude as the Main Chronobiological Abnormality," <i>Psychiatry Res.</i> 28:263-278 (1989).						
		<u> </u>						

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.